Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Sponsor: Ariad Pharmaceuticals
Terminated
Study terminated based on evaluation of safety data.
Other terminated trials from Ariad Pharmaceuticals
Other Chronic Myeloid Leukemia trials with similar outcome
A PHASE3 clinical study on Chronic Myeloid Leukemia, this trial is terminated or withdrawn. The trial is conducted by Ariad Pharmaceuticals and has accumulated 8 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Jun 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ariad Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Aachen, Germany , Aarau, Switzerland , Adelaide, Australia , Albuquerque, United States , Amsterdam, Netherlands , Ann Arbor, United States , Atlanta, United States , Austin, United States , Badalona, Spain and 139 more locations